Search Results - "Denzlinger, C."

CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer – Final results by Sinn, M., Liersch, T., Riess, H., Gellert, K., Stübs, P., Waldschmidt, D., Lammert, F., Maschmeyer, G., Bechstein, W., Bitzer, M., Denzlinger, C., Hofheinz, R., Lindig, U., Ghadimi, M., Hinke, A., Striefler, J.K., Pelzer, U., Bischoff, S., Bahra, M., Oettle, H.

“…CONKO-006 was designed for patients with pancreatic adenocarcinoma with postsurgical R1 residual status to evaluate the efficacy and safety of the combination…”
Get full text

Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110) by Boukovala, M., Modest, D.P., Ricard, I., Fischer von Weikersthal, L., Decker, T., Vehling-Kaiser, U., Uhlig, J., Schenk, M., Freiberg-Richter, J., Peuser, B., Denzlinger, C., Peveling Genannt Reddemann, C., Graeven, U., Schuch, G., Schwaner, I., Heinrich, K., Neumann, J., Jung, A., Held, S., Stintzing, S., Heinemann, V., Michl, M.

“…The inflammation-based modified Glasgow Prognostic Score (mGPS) combines serum levels of C-reactive protein and albumin and was shown to predict survival in…”
Get full text

Age and RAS status to select patients with metastatic colorectal cancer (mCRC) for initial sequential versus combination therapy including fluoropyrimidines (FP), irinotecan (Iri) and bevacizumab (Bev): XELAVIRI- study by Modest, D., von Weikersthal, L. Fischer, Decker, T., Vehling-Kaiser, U., Uhlig, J., Schenk, M., Freiberg-Richter, J., Peuser, B., Denzlinger, C., Reddemann, C. Peveling genannt, Graeven, U., Schuch, G., Schwaner, I., Stahler, A., Jung, A., Kirchner, T., Held, S., Stintzing, S., Giessen-Jung, C., Heinemann, V.

Get full text

Gemtuzumab ozogamicin (Mylotarg ) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups by AMADORI, S, SUCIU, S, PRUIJT, J, NOBILE, F, CASSIBBA, V, MARIE, J.-P, BEELDENS, F, BAILA, L, VIGNETTI, M, DE WITTE, T, STASI, R, WILLEMZE, R, MANDELLI, F, SELLESLAG, D, DENZLINGER, C, MUUS, P, STAUDER, R, BERNEMAN, Z

“…The therapeutic activity and toxicity profile of gemtuzumab ozogamicin were assessed in 40 patients >60 years of age with acute myeloid leukemia (AML) who were…”
Get full text

Long-term treatment of advanced hepatocellular carcinoma with the tyrosine kinase inhibitor erlotinib (Tarceva)--a case report by Hass, H G, Denzlinger, C

“…Hepatocellular carcinoma (HCC) is the 5th most common human malignancy with an increasing incidence in western countries and still unsatisfactory median…”
Get more information

Leukotrienes as Mediators in Tissue Trauma by Denzlinger, C., Rapp, S., Hagmann, W., Keppler, D.

“…A significant increase in the production of cysteinyl leukotrienes was observed after mechanical or thermal trauma in the anesthesized rat. The amount of…”
Get full text

Complete Remission of Third Recurrence of Acute Myeloid Leukemia after Treatment with Imatinib (STI-571) by Schittenhelm, M., Aichele, O., Kröber, S.M., Brümmendorf, T., Kanz, L., Denzlinger, C.

“…We report the case of a 76-year old patient with third relapse of AML who was successfully treated with Imatinib. The decision to try Imatinib was guided by…”
Get full text

Poor response rate to a continuous schedule of Amifostine therapy for ‘low/intermediate risk’ myelodysplastic patients by BOWEN, D. T, BRUGGER, C. D, CULLIGAN, D, GELLY, K, ADLAKHA, S, GROVES, M, HEPBURN, M, KANZ, L

“…Ineffective haemopoiesis leading to cytopenia presents the major clinical management problem for patients with myelodysplasia (MDS). Preliminary studies have…”
Get full text

High‐grade lymphoma mimicking bone crisis in Gaucher's disease by Manz, M., Riessen, R., Poll, L., Dohmen, B., Kaiserling, E., Krück, W., Laniado, M., Kanz, L., Denzlinger, C.

“…A 33‐year‐old woman with type 1 Gaucher's disease developed painful swelling of her right tibia. Initial diagnostics suggested a typical bone crisis. However,…”
Get full text

P-179 Prognostic and predictive value of CEA before initiation of therapy in the XELAVIRI trial by Alig, A., Heinemann, V., Fischer von Weikersthal, L., Decker, T., Vehling-Kaiser, U., Uhlig, J., Schenk, M., Denzlinger, C., Stahler, A., Held, S., Stintzing, S., Modest, D., Heinrich, K.

Get full text

1301P Sequential therapy of metastatic pancreatic ductal adenocarcinoma (PDAC) after failure of gemcitabine plus nab-paclitaxel with either 5-FU/folinic acid (5FU/LV) plus irinotecan (FOLFIRI) followed by 5FU/LV plus oxaliplatin (OFF) or the reverse sequence: The PANTHEON trial (AIO PAK 0116) by Modest, D.P., Heinemann, V., Schütt, P., Angermeier, S., Haberkorn, M., Waidmann, O., Graeven, U., Wille, K., Kunzmann, V., Henze, L., Constantin, C., De Wit, M., Denzlinger, C., Kurreck, A., Alig, A.H.S., Stahler, A., Pelzer, U., Stintzing, S., Oettle, H.

Get full text

Human parvovirus B19-associated disease in bone marrow transplantation by SCHLEUNING, M, JÄGER, G, HOLLER, E, HILL, W, THOMSSEN, C, DENZLINGER, C, LORENZ, T, LEDDEROSE, G, WILMANNS, W, KOLB, H.-J

“…Human parvovirus B19 can persist in immunocompromised patients and may produce severe clinical illness. In this retrospective study the incidence of…”
Get full text

High-risk additional chromosomal abnormalities at low blast counts herald death by CML by Hehlmann, Rüdiger, Voskanyan, Astghik, Lauseker, Michael, Pfirrmann, Markus, Kalmanti, Lida, Rinaldetti, Sebastien, Kohlbrenner, Katharina, Haferlach, Claudia, Schlegelberger, Brigitte, Fabarius, Alice, Seifarth, Wolfgang, Spieß, Birgit, Wuchter, Patrick, Krause, Stefan, Kolb, Hans-Jochem, Neubauer, Andreas, Hossfeld, Dieter K., Nerl, Christoph, Gratwohl, Alois, Baerlocher, Gabriela M., Burchert, Andreas, Brümmendorf, Tim H., Hasford, Jörg, Hochhaus, Andreas, Saußele, Susanne, Baccarani, Michele

“…Blast crisis is one of the remaining challenges in chronic myeloid leukemia (CML). Whether additional chromosomal abnormalities (ACAs) enable an earlier…”
Get full text

Sustained complete remission of recurrent acute myeloid leukaemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintenance by Radsak, M P, Salih, H R, Sökler, M, Kanz, L, Denzlinger, C

“…Leukemia (2002) 16, 1870-1871. doi:10.1038/sj.leu.2402594…”
Get full text

IL-4 renders mast cells functionally responsive to endothelin-1 by Egger, D, Geuenich, S, Denzlinger, C, Schmitt, E, Mailhammer, R, Ehrenreich, H, Dormer, P, Hultner, L

“…It has previously been shown that mouse bone marrow-derived mast cells (BMMC) synthesize and secrete endothelin-1 (ET-1) and express ETA-type endothelin…”
Get full text

Metabolism and analysis of cysteinyl leukotrienes in the monkey by Denzlinger, C, Guhlmann, A, Scheuber, P H, Wilker, D, Hammer, D K, Keppler, D

“…Predominant hepatobiliary elimination from blood and subsequent enterohepatic circulation of cysteinyl leukotrienes is demonstrated in the monkey Macaca…”
Get full text

Release of prostaglandin D2 by murine mast cells: importance of metabolite formation for antiproliferative activity by Haberl, C, Hültner, L, Flügel, A, Falk, M, Geuenich, S, Wilmanns, W, Denzlinger, C

“…Prostaglandin (PG) D2, PGJ2 and delta12-PGJ2 are antiproliferative eicosanoids. We investigated the production of PGD2 by murine bone marrow-derived mast cells…”
Get full text

Potentially therapeutically relevant differences of antisense oligonucleotide uptake in CD34+ hematopoietic stem cells, leukemic blasts and cancer cells from patients by Seitz, G, Kohler, G, Nehmzow, M, Lorenz, G, Denzlinger, C, Müller, C, Bader, P, Brischwein, K, Beck, J F

“…Antisense oligonucleotide (ON) technology, e.g. against drug resistance or antiapoptotic factors, may play an important role in future cancer chemotherapy. An…”
Get more information

Afatinib in Non‐Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors by Schumann, Christian, Sebastian, Martin, Sadjadian, Parvis, Märten, Angela, Abdollahi, A., Aries, S.P., Arntzen, C., Atmaca, A., Basara, N., Borchard, B., Bos, M., Brugger, W., Budweiser, S., Corduan, K., Cortes‐Incio, D., Dallmeier, B., Denzlinger, C., Dittrich, I., Engel‐Riedel, W., Faehling, M., Fertl, A., Fischer, J.R., Fleckenstein, D., Folprecht, G., Forstbauer, A., France, Y., Frickhofen, N., Gardizi, M., Gauler, T., Gessner, C., Gökkurt, E., Görner, M., Grah, C., Greeve, J., Greiner, J., Grohé, C., Grüning, W., Guggenberger, D., Heinrich, B., Hense, G., Hoiczyk, M., Huber, R.M., Illerhaus, G., Jacobs, G., Jung, P., Kern, J., Kersten, J., Kiehl, M., Kisro, J., Knipp, H., Ko, Y.D., Koch, J.U., Koehne, C.H., Kollmeier, J., Kommer, A., Körber, W., Krause, G., Krügel, R., Leistner, R., Liebers, U., Lommatzsch, M., Maintz, C., Mohr, M., Neumeister, W., Overbeck, T., Panse, J., Pelzer, T., Peters, K., Planker, M., Reissig, A., Ritter, M., Sadjadian, P., Sandritter, B., Schatz, M., Scheffler, M., Schmid‐Bindert, G., Schneider, C.P., Schneider‐Kappus, W., Schreiber, J., Schütte, W., Schütz, S., Sebastian, M., Serke, M., Staiger, H., Stehle, I., Stengele, K., Stöhlmacher‐Williams, J., Strapatsas, T., Sulzbach, B., Tessmer, A., Thomas, M., Ukena, D., Wagner, B., Wagner‐Hug, D., Witt, C., Wohlleber, M., Wolf, J., Wricke, K., Zaba, O., Zander, I.

“…Background. Afatinib, an irreversible ErbB family blocker, is approved for treatment of patients with previously untreated non‐small cell lung cancer (NSCLC)…”
Get full text

Release of prostaglandin D_2 by murine mast cells: importance of metabolite formation for antiproliferative activity by C. Haberl, L. Hültner, A. Flügel, M. Falk, S. Geuenich, W. Wilmanns, C. Denzlinger

“…PROSTAGLANDIN (PG) D_2 , PGJ_2 and Δ^(12) -PGJ_2 are antiproliferative eicosanoids. We investigated the production of PGD_2 by murine bone marrow-derived mast…”
Get full text